# Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

> **NCT03790072** · PHASE1 · COMPLETED · sponsor: **TC Biopharm** · enrollment: 10 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** OmnImmune®

## Key facts

- **NCT ID:** NCT03790072
- **Lead sponsor:** TC Biopharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-27
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-03-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790072, "Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03790072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*